ALFUZOSINE LP EG 10 mg

Generic drug of Xatral LP
Therapeutic class: Urology nephrology
active ingredients: Alfuzosin
laboratory: EG Labo

Indication

- Treatment of functional symptoms of benign prostatic hypertrophy. - Bladder adjuvant treatment in acute urine retention related to benign prostatic hypertrophy.

Dosage ALFUZOSINE LP EG 10 mg prolonged release tablet Box of 30

Oral way.
The tablet should be swallowed whole, without being crunched, with a glass of water (see section warnings and precautions for use).
Adults:
- The recommended dosage is 1 10 mg tablet daily, to be taken immediately after the evening meal.
- Bladder adjuvant treatment in acute urine retention related to benign prostatic hypertrophy:
. The recommended dosage is 1 10 mg tablet daily, to be taken after the meal, from the first day of urethral catheterization.
. The treatment is administered for 3 to 4 days including 2 to 3 days during the catheterization and 1 day after the withdrawal of the latter.

Against indications

CONTRAINDICATED:
Hypersensitivity to alfuzosin and / or any of the excipients.
- Orthostatic hypotension.
- Hepatic insufficiency.
- Severe renal insufficiency (creatinine clearance <30 ml / min).
- Excipients-related: Due to the presence of lactose, this medicinal product should not be used in cases of congenital galactosemia, glucose-galactose malabsorption syndrome or lactase deficiency.
- The therapeutic indication does not concern the woman.
NOT RECOMMENDED :
Associations advised against : antihypertensive alpha blockers (prazosin, urapidil, minoxidil); ketoconazole, itraconazole, ritonavir, clarithromycin, erythromycin.

Adverse effects Alfuzosine LP EG

- CNS disorders and psychiatric disorders:
. Frequent (> = 1% - <10%) : dizziness, dizziness, malaise, headache.
. Uncommon (> = 0.1% - <1%) : dizziness, drowsiness.
- Cardiovascular disorders:
. Uncommon (> = 0.1% - <1%) : tachycardia, palpitations, orthostatic hypotension, syncope.
. Very rare (<0.01%) : angina pectoris in patients with a history of coronary artery disease (see section cautionary statements and precautions for use).
- Respiratory system disorders:
Uncommon (> = 0.1% - <1%) : nasal congestion.
- Gastrointestinal disorders:
. Frequent (> = 1% - <10%) : nausea, abdominal pain.
. Uncommon (> = 0.1% - <1%) : diarrhea, dry mouth.
- Skin manifestations:
. Uncommon (> = 0.1% - <1%) : rash, pruritus.
. Very rare (<0.01%) : urticaria, angioneurotic edema.
- General events:
. Frequent (> = 1% - <10%) : asthenia.
. Uncommon (> = 0.1% - <1%) : flushes, edema, chest pain (see section cautionary statements and precautions for use).